| [1] |
Wang JZ, Liu BG, Zhang Y. Pin1-based diagnostic and therapeutic strategies for breast cancer[J]. Pharmacol Res,2015,93:28-35.
|
| [2] |
Krishnan N, Titus MA, Thapar R. The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins[J]. PLoS One,2014,9(1):e85427.
|
| [3] |
Litchfield DW, Shilton BH, Brandl CJ, et al. Pin1: Intimate involvement with the regulatory protein kinase networks in the global phosphorylation landscape[J]. Biochim Biophys Acta,2015,1850(10):2077-2086.
|
| [4] |
Tong Y, Ying H, Liu R, et al. Pin1 inhibits PP2A-mediated Rb dephosphorylation in regulation of cell cycle and S-phase DNA damage[J]. Cell Death Dis,2015,6:e1640.
|
| [5] |
Wang J, Ray PS, Sim MS, et al. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappaB signaling[J]. Oncogene,2012,31(45):4798-4802.
|
| [6] |
Girardini JE, Napoli M, Piazza S, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer[J]. Cancer Cell, 2011,20(1):79-91.
|
| [7] |
Farrell AS, Pelz C, Wang X, et al. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis[J]. Mol Cell Biol,2013,33(15):2930-2949.
|
| [8] |
Bao L, Kimzey A, Sauter G, et al. Prevalent overexpression of prolyl isomerase Pin1 in human cancers[J]. Am J Pathol, 2004, 164(5):1727-1737.
|
| [9] |
Lam PB, Burga LN, Wu BP, et al. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability[J]. Mol Cancer,2008,7:91.
|
| [10] |
Kaklamani VG, Jeruss JS, Hughes E, et al. Phase Ⅱneoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579) [J]. Breast Cancer Res Treat,2015,151(3):629-638.
|
| [11] |
Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1[J]. EMBO J,2001,20(13):3459-3472.
|
| [12] |
Ding Q, Huo L, Yang JY, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer[J]. Cancer Res, 2008, 68(15):6109-6117.
|
| [13] |
Rajbhandari P, Schalper KA, Solodin NM, et al. Pin1 modulates ERalpha levels in breast cancer through inhibition of phosphorylationdependent ubiquitination and degradation [J]. Oncogene, 2014,33(11):1438-1447.
|
| [14] |
Lee KY, Lee JW, Nam HJ, et al. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells[J]. Mol Cells,2011,32(1):107-111.
|
| [15] |
Choi HJ, Kim JY, Lim SC, et al. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression[J]. Br J Pharmacol, 2015, 172(21):5096-5109.
|
| [16] |
Ryo A, Liou YC, Wulf G, et al. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells[J].Mol Cell Biol,2002,22(15):5281-5295.
|
| [17] |
Pulikkan JA, Dengler V, Peer Zada AA, et al. Elevated PIN1 expression by C/EBPalpha-p30blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML[J]. Leukemia,2010,24(5):914-923.
|
| [18] |
Zhenzhen L, Ning S, Xianghua L. Association of rs2233678 and rs2233679 polymorphisms in the PIN1 gene with cancer risk: a metaanalysis[J]. Tumour Biol,2014,35(1):433-440.
|
| [19] |
Tao LJ,Chen YS,Yao L,et al. Pin1 promoter polymorphism(-842 G＞C) contributes to a decreased risk of cancer: Evidence from metaanalysis[J]. Oncol Lett,2014,8(3):1360-1366.
|
| [20] |
Cho YS, Park SY, Kim DJ, et al. TPA-induced cell transformation provokes a complex formation between Pin1 and 90 kDa ribosomal protein S6 kinase 2[J]. Mol Cell Biochem,2012,367(1/2):85-92.
|
| [21] |
Kim G,Khanal P,Kim JY,et al. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer[J]. Mol Carcinog,2015,54(6):440-448.
|
| [22] |
Rangasamy V, Mishra R, Sondarva G, et al. Mixed-lineage kinase 3 phosphorylates prolyl-isomerase Pin1 to regulate its nuclear translocation and cellular function[J]. Proc Natl Acad Sci U S A,2012,109(21):8149-8154.
|
| [23] |
Lee TH, Chen CH, Suizu F, et al. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function[J]. Mol Cell,2011,42(2):147-159.
|
| [24] |
Chen CH, Chang CC, Lee TH, et al. SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function[J]. Cancer Res,2013,73(13):3951-3962.
|
| [25] |
Rajbhandari P, Ozers MS, Solodin NM, et al. Peptidylprolyl isomerase Pin1 directly enhances the DNA binding functions of estrogen receptor α[J]. J Biol Chem,2015,290(22):13 749-13 762.
|
| [26] |
Rajbhandari P, Finn G, Solodin NM, et al. Regulation of estrogen receptor alpha N-terminus conformation and function by peptidyl prolyl isomerase Pin1[J].Mol Cell Biol,2012,32(2):445-457.
|
| [27] |
Lucchetti C, Caligiuri I, Toffoli G, et al. The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor alpha in breast cancer[J]. PLoS One,2013,8(2):e55355.
|
| [28] |
Stanya KJ, Liu Y, Means AR, et al. Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT[J]. J Cell Biol, 2008,183(1):49-61.
|
| [29] |
Khanal P, Yun HJ, Lim SC, et al. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells[J]. Oncogene, 2012,31(34):3845-3856.
|
| [30] |
Ryo A, Wulf G, Lee TH, et al. Pinning down HER2-ER crosstalk in SMRT regulation[J]. Trends Biochem Sci,2009,34(4):162-165.
|
| [31] |
Kim MR, Choi HK, Cho KB, et al. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells[J]. Cancer Sci,2009,100(10):1834-1841.
|
| [32] |
Kim MR, Choi HS, Yang JW, et al. Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression[J]. Mol Cancer Ther,2009,8(8):2163-2171.
|
| [33] |
Han HJ, Kwon N, Choi MA, et al. Peptidyl prolyl isomerase PIN1 directly binds to and stabilizes hypoxia-inducible factor-1α[J]. PLoS One,2016,11(1):e0147038.
|
| [34] |
Kim JA, Kim MR, Kim O, et al. Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition[J]. Food Chem Toxicol,2012,50(10):3625-3634.
|
| [35] |
Jo A, Yun HJ, Kim JY, et al. Prolyl isomerase PIN1 negatively regulates SGK1 stability to mediate tamoxifen resistance in breast cancer cells[J]. Anticancer Res,2015,35(2):785-794.
|
| [36] |
Khanal P, Namgoong GM, Kang BS, et al. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signalregulated kinase kinase 1[J]. Molecular Cancer Ther, 2010, 9(3):606-616.
|
| [37] |
Puig T, Aguilar H, Cufi S, et al. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines[J]. Breast Cancer Res,2011,13(6):R131.
|
| [38] |
Yan C, Wei H, Minjuan Z, et al. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells[J]. PLoS One, 2014, 9(5):e97697.
|
| [39] |
Yun HJ, Kim JY, Kim G, et al. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression[J]. Anticancer Res,2014,34(3):1409-1416.
|
| [40] |
Khan A, Aljarbou AN, Aldebasi YH, et al. Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway[J]. Cancer Epidemiol,2014,38(6):765-772.
|
| [41] |
Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: obstacles to therapy[J]. Cancer Lett,2013,338(1):57-62.
|
| [42] |
Ansieau S. EMT in breast cancer stem cell generation[J]. Cancer Lett,2013,338(1):63-68.
|
| [43] |
Shah M, Allegrucci C. Keeping an open mind: highlights and controversies of the breast cancer stem cell theory[J]. Breast Cancer(Dove Med Press),2012,4:155-166.
|
| [44] |
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelialmesenchymal transition [J]. Nat Rev Mol Cell Biol, 2014, 15(3):178-196.
|
| [45] |
Luo ML, Gong C, Chen CH, et al. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer[J]. Cancer Res,2014,74(13):3603-3616.
|
| [46] |
Zhang X, Zhang B, Gao J, et al. Regulation of the microRNA 200b(miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anoikis[J]. J Biol Chem,2013,288(45):32 742-32 752.
|
| [47] |
Rustighi A, Zannini A, Tiberi L, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast[J]. EMBO Mol Med,2014,6(1):99-119.
|
| [48] |
Rustighi A, Tiberi L, Soldano A, et al. The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer[J]. Nat Cell Biol,2009,11(2):133-142.
|
| [49] |
Luo ML, Gong C, Chen CH, et al. The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation[J]. Cell Rep,2015,11(1):111-124.
|
| [50] |
Wei S, Kozono S,Kats L,et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer[J].Nat Med,2015,21(5):457-466.
|
| [51] |
Hu YG, Shen YF, Li Y. Effect of Pin1 inhibitor juglone on proliferation, migration and angiogenic ability of breast cancer cell line MCF7Adr[J]. J Huazhong Univ Sci Technolog Med Sci, 2015,35(4):531-534.
|
| [52] |
Hahm ER, Singh SV. Diallyl trisulfide inhibits estrogen receptor-alpha activity in human breast cancer cells[J]. Breast Cancer Res Treat,2014,144(1):47-57.
|
| [53] |
Kim JH, Jung JH, Kim SH, et al. Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1/p53 association[J]. Phytother Res,2014,28(2):238-244.
|
| [54] |
Moore JD, Potter A. Pin1 inhibitors: Pitfalls, progress and cellular pharmacology [J]. Bioorg Med Chem Lett, 2013, 23 (15):4283-4291.
|
| [55] |
Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation[J]. Nat Med,2008,14(12):1333-1342.
|
| [56] |
Guo C, Hou X, Dong L, et al. Structure-based design of novel human Pin1 inhibitors (Ⅲ): optimizing affinity beyond the phosphate recognition pocket [J]. Bioorg Med Chem Lett, 2014, 24 (17):4187-4191.
|